Blog

Paul Kelly: The role of Space OAR Vue in modifying the risk of rectal side effects

Paul Kelly/www.corkbeo.ie

Oct 13, 2024, 22:29

Paul Kelly: The role of Space OAR Vue in modifying the risk of rectal side effects

Paul Kelly, Radiation Oncologist at Bon Secours Hospital Cork UPMC, Ireland shared a post by Karen Molan, Senior Clinical Researcher at on X, adding:

“Great to make a contribution to this prostate cancer radiotherapy SBRT clinical trial, the subject of which is the role of Boston Scientific EMEA – Urology Space OAR Vue in modifying the risk of rectal side effects.

Patients are never the barrier to clinical trial recruitment.”

Quoting Karen Molan:

“Trial Activity.
SABRE Trial Achievement
20 Patients recruited.”

Boston Scientific EMEA - Urology cancer cancer awareness cancer care CancerTrialsIreland fight against cancer Global fight against cancer OncoDaily Oncology Paul Kelly prostate cancer prostate cancer radiotherapy QOL radiotherapy SABR SBRT clinical trial

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage